SAKK - a trial to evaluate antitumor efficacy of Faslodex® after aromatase inhibitor failure in advanced breast cancer
Study identifier:9238SZ/0001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex® (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors
Medical condition
Breast Neoplasms
Phase
Phase 2
Healthy volunteers
No
Study drug
Fulvestrant
Sex
Female
Actual Enrollment
93
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Mar 2000
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Feb 2007 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Switzerland Medical Director
AstraZeneca
